Wall Street analyst estimates for Liminatus Pharma, Inc. Class A Common Stock (LIMN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Valuation Ratios
| Price / Book | 5.08 |
| EV / EBITDA | -0.27 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $3.8M | $1.9M | $3.8M | $2.7M | 0 |
| Selling, General & Admin | $197000 | $856000 | $1.1M | $645000 | $3.0M |
| Operating Expenses | $2.5M | $2.7M | $2.6M | $2.9M | $3.0M |
| Operating Income | -$2.5M | -$2.7M | -$2.6M | -$2.9M | -$3.0M |
| EBITDA | $4.4M | -$2.7M | -$1.1M | -$2.7M | -$10.0M |
| Interest Expense | 0 | $219000 | $175000 | $138102 | $215903 |
| Pre-tax Income | $4.4M | -$2.9M | -$1.2M | -$2.9M | -$10.2M |
| Income Tax | 0 | 0 | $33987 | $18841 | 0 |
| Net Income | $4.4M | -$2.9M | -$1.2M | -$2.9M | -$10.2M |
| EPS | $6.50 | $-4.12 | $-7.50 | $-20.00 | $-21.50 |
| EPS (Diluted) | $6.50 | $-4.12 | $-7.50 | $-20.00 | $-21.50 |
| Shares Outstanding (Diluted) | $690000 | $688565 | $160251 | $143832 | $475071 |
Price
| Price | $3.33 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ATHE · BTAI · DYAI · EVAX · GBIO · JSPR · MAIA
Explore sector: Healthcare · Biotechnology
More sections of LIMN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks